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to enter the market and boost competition in the sector. However, manufacturers 
will have to ensure that biosimilars are sensibly price and also put proper sales 
and marketing support behind the product to address the low awareness amongst 
physicians and local payers.
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Objectives: Biologics represent major advances in the treatment of rheumatoid 
arthritis (RA) with eight agents available on the market by 2010. In the Medicare 
program, 3 agents are Part B covered infusibles, while the remaining five are Part D 
covered self-injectables. This study examines the association between cost sharing 
and the initiation and choice of RA biologic (Part D vs. Part B) in Medicare benefi-
ciaries. MethOds: Fee-for-service beneficiaries with continuous Part D coverage 
and RA (ICD-9-CM 714.xx) in the 2010 Medicare 5% files (N= 12,923) were examined. 
Dependent variables included initiation of any biologic among all RA patients and 
the use of a Part D (vs. Part B) biologic among biologic users. To isolate the effect of 
the specialty tier cost-sharing (from that of the donut hole) we further identified 
whether a Part D biologic was first initiated in the initial coverage limit (ICL) phase 
or not. The key independent variable was the beneficiary’s low income subsidy 
(LIS) status i.e. non-LIS vs. full-LIS as a proxy for higher (initially 25% to 35% coin-
surance followed by donut hole) vs. lower cost-sharing ($3-$5 copay), respectively. 
Multivariate logistic regressions with robust clustered standard errors at the plan 
level were estimated. Results: Overall RA biologic use was 17% in the sample (10 
% Part B and 7% Part D biologics). Compared to full-LIS patients, non-LIS patients 
had lower odds of initiating any RA biologic in the year (OR 0.84, 95% CI 0.75-0.94). 
Among biologic users, non-LIS patients were less likely to use a Part D biologic in 
the entire year (OR 0.19, 95% CI 0.15-0.24) and in the ICL-phase (OR 0.22, 95% CI 
0.17-0.28). cOnclusiOns: High cost sharing due to specialty tiers and the coverage 
gap under Part D may be associated with non-LIS patients foregoing use of any RA 
biologic or substituting with infusible biologics under Part B.
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Objectives: Real-world treatment behavior data among patients with Dupuytren’s 
contracture (DC) with a palpable cord are limited. The objective of this study was to 
assess real-world treatment behavior following Xiaflex®(collagenase clostridium 
histolyticum) or fasciectomy among adult DC patients. MethOds: A retrospec-
tive cohort analysis was conducted using the IMS LifeLink™ Health Plan Claims 
Database. Patients ≥ 18 years between 2/1/2010–12/31/2011, with a treated finger/
joint with Xiaflex or fasciectomy (index event), who were continuously enrolled 
both in the 12-month pre- and post-index periods, and had ≥ 1 DC diagnosis code 
in the pre-index period were included. A second treatment was defined as having 
occurred following a gap of ≥ 30 days from the index event. Descriptive statistics 
were reported and logistic regression and Cox Proportional Hazards models were 
used to adjust for baseline differences. Results: 309 Xiaflex/1,264 fasciectomy 
patients were included. Xiaflex patients were significantly older than fasciec-
tomy patients (64.28 vs. 61.50 years; p< 0.0001). Majority of all patients were male. 
Fasciectomy cohort had a greater proportion of patients with a second treatment 
than Xiaflex cohort (54% vs. 14%; p> 0.05). Nearly all patients received Xiaflex as 
their second treatment (99.12% vs.100% respectively). Demographic and clinical 
characteristics of patients receiving a second treatment among both cohorts were 
similar to those who did not receive a second treatment. After adjusting for baseline 
confounders, fasciectomy patients were 8.3-times more likely to have a second 
treatment compared to Xiaflex patients (OR: 8.28; 95% CI: 5.79-11.85; p< 0.0001). 
Older patients, patients with hyperlipidemia, hypothyroidsm, higher Charlson 
Comorbidity Index scores, and higher pre-index health care costs had a greater 
hazard of having a second treatment (all comparisons p< 0.05). cOnclusiOns: 
Xiaflex was used as a second treatment among nearly all DC patients. As such, 
fasciectomy patients may be candidates to be replaced by Xiaflex to reduce the risk 
and costs of a second treatment.
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Objectives: Various medications are commonly used to manage Rheumatoid 
Arthritis (RA). This study examined drug utilization patterns and factors associ-
ated with the use of medications by RA patients. MethOds: Data from the 2006-
2010 National Ambulatory Care Survey (NAMCS) and the outpatient department 
component of the National Hospital Ambulatory Medical Care Survey (NHAMCS) 
were used to examine the RA related ambulatory visits. RA medications were 
classified as NSAIDS and analgesics, corticosteroids, and disease modifying Anti-
rheumatic drugs (DMARDs). Bivariate chi-square analysis and multiple logistic 
regression analysis were performed to evaluate the factors associated with pre-
scribing of RA medications. SAS survey procedures that adjust for the complex 
sampling procedure of national surveys were used to conduct bivariate and 
multivariate analyses. Results: An average of 3.57 million (0.33%) visits was 
made by patients with RA from 2006 to 2010. Majority of these visits were 
made by females (76.75%), Whites (88.50%) and individuals aged 18-64 years old 
(61.53%). More than two third of the RA patients were prescribed anti-rheumatic 
Benefits associated with early detection and treatment of RA with biologics warrant 
closer scrutiny to alleviate patient burden.
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Objectives: Given the evidence showed that bone disorders were one of the top 
three prevalent chronic conditions among the elderly in Taiwan, the aim of this 
study was to explore the different characteristic, health status, health care utiliza-
tion between those who suffered from bone disorders or not among the elderly 
in Taiwan. MethOds: The data used for this study was obtained from the 2005 
National Health Interview Survey (NHIS) databases in Taiwan. The interviewees who 
reported to have “osteoporosis” or “osteoarthritis” were grouped into bone disorder 
group. Otherwise were non-bone disorder group. The appropriate descriptive sta-
tistics with sampling weights and inferential analysis approaches were applied on 
those responses for basic demographics, perceived health status, and self- report 
health care utilization. Results: Of 2727 elderly interviewees in 2005 NHIS, 35.2% 
reported to have bone disorders and their demographic characteristics were not 
statistically significant different from the other group, except the proportion of 
female. (65.0% vs 43%). While bone disorder group tended to have more chronic 
conditions than non-bone disorder group, they were also more likely to report fall 
experiences and worse health status Further, they tended to consume more utiliza-
tion of emergency care, hospital stay , dental care and Traditional Chinese medicine 
(TCM) service in past one year (all pvalues < 0.05) than otherwise. cOnclusiOns: 
Elderly with and without bone disorders in Taiwan were different not only in the 
demographic characteristics but also in their diseases, health status and health 
care utilization, including TCM service. Further comprehensive analyses would be 
needed to explore the extent of contributing factors on the health care utilization 
among elderly patients suffered from bone disorders.
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Objectives: Until 2012, only the biological agents adalimumab, etanercept and 
infliximab were available in the Brazilian public health system (SUS) to treat 
Rheumatoid Arthritis (RA). Since July 2013, abatacept, certolizumab, golimumab, 
rituximab and tocilizumab were also made available, according to the treatment 
algorithm presented in the Brazilian Guidelines. The aim of this study is analyze 
the budget impact of these new technologies, by the MoH perspective. MethOds: 
The number of patients with RA treated with the new biologicals in the SUS was 
estimated by the ratio between the amount dispensed in 2013 and its recommended 
dosage. The data about the older biological agents were extracted from the SUS 
database (Datasus). The drug acquisition costs were used to calculate the rela-
tive treatment cost among the different therapeutic alternatives (current values; 
exchange rate: US$ 1 = R$ 2.36). The budget impact was calculated by comparing the 
new biologic treatment costs (abatacept, certolizumab, golimumab, rituximab and 
tocilizumab) and a potential costs in a hypothetical scenario without new agents 
available (only considering adalimumab, etanercept and infliximab). Results: From 
July to December 2013, 3,959 patients with RA were treated with new biologicals, 
implying a total spent of US$ 18,905,770.06. The mean monthly cost of treatment per 
patient was US$ 759.91, with higher values for abatacept (US$ 1,290.56) and lower 
for rituximab (US$ 579.10). If all of these patients were treated with the older agents, 
the total costs would sum up to US$ 41,497,979.83. Thus, the offer of new drugs in 
the SUS has saved a total of US$ 25,592,209.32 (54.44%) in 2013. cOnclusiOns: 
Offering new biologicals for RA allowed the SUS to expand the access to medicines 
and treatment of patients refractory to anti-TNF, also resulting potential savings 
for the SUS resources.
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Objectives: Following the recent approval of infliximab in the EU, the objectives 
were to understand EU payer and physicians expectations of the new biosimilars. 
How could biosimilars influence payer and physician decision-making and what 
must manufacturers do to achieve success? MethOds: Secondary research to 
understand payer drivers & local decision-making processes followed by 1:1stake-
holder interviews with 12 EU physicians on decision-making committee’s and 6 
EU Senior payers. Results: Awareness of biosimilars amongst physicians is cur-
rently low. Just 8% of physicians questioned in the EU spontaneously mentioned 
biosimilars as products in development, with Remsima/Inflectra the only biosimi-
lar mentioned specifically by name. Only 35% of the physicians said they would 
definitely consider prescribing biosimilars for Rheumatoid Arthritis within one 
year of launch. Payers are anticipating a 30% saving verses the originator drug. 
Payers warned that manufacturers need to treat biosimilars as if they were branded 
medicines, and ensure a proper commercial strategy. cOnclusiOns: The recent 
approval of Hospira’s Inflectra (infliximab) may mark a turning point for biosimilars 
in Europe. While follow-on biologics have been on the EU market since 2006, Inflectra 
was the first such approval for a monoclonal antibody – larger, more complex mol-
ecules than the 14 biosimilars previously cleared by the EMA. The broader context 
is that the exhaustion of patent and other intellectual-property rights on originator 
biologicals over the next decade affords an unparalleled opportunity for biosimilars 
